Alkermes plc - Ordinary Shares (ALKS) analyst actions
Rating and price-target actions on ALKS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ALKS overview →
4 measured ALKS analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 | Press release | +2.08% | -1.27% | |
| Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia | Press release | +0.12% | -0.94% | |
| Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 | Press release | -0.07% | -0.99% | |
| Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 | Press release | +0.66% | +1.61% |
Keep exploring
More ALKS: earnings → · SEC filings → · ALKS overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. (CRNX) | 482 | 0.00% | 50% |
| Medtronic plc. Ordinary Shares (MDT) | 481 | -0.06% | 45% |
| HCA Healthcare, Inc. (HCA) | 479 | +0.30% | 62% |
| NEOS THERAPEUTICS (NEOS) | 479 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.